CGT

868개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved868 programs
CGTCurated CoreFDAKiteApproved

axicabtagene ciloleucel (Yescarta, axi-cel)

LBCL, FL · CD19

#CD19#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 68Status Approved
CGTCurated CoreFDAJohnson & JohnsonApproved

ciltacabtagene autoleucel (Carvykti, cilta-cel, LCAR-B38M, JNJ-68284528)

Relapsed or refractory multiple myeloma · BCMA

#BCMA#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 29Status Approved
CGTLimited DatastaleThomas Martin, MDPhase 1

Chimeric Antigen Receptor T cells (CAR-T, Chimeric Antigen Receptor T cells, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA)

Multiple Myeloma; Recurrent Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 211Status Discontinued
CGTStandard DatabasestaleAstraZenecaPhase 2

autologous CD19-directed chimeric antigen receptor (CAR, autologous CD19-directed chimeric antigen receptor, autologous CD19-directed chimeric antigen receptor (CAR) T-cells)

Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 154Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-B Cell Maturation Antigen (BCMA, Anti-B Cell Maturation Antigen, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · BCMA

#BCMA#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 131Status Active
CGTLimited DatastaleNeotropixPhase 1

biological agent (Seneca Valley Virus, Seneca Valley Virus (biological agent))

Carcinoid; Neuroendocrine · Carcinoid

#Carcinoid#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 93Status Active
CGTLimited DatastaleTcelltech Inc.Phase 1

Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell, Anti-B7-H3 Chimeric Antigen Receptor T-Cell, Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103)

Solid Tumors · B7-H3

#B7-H3#CGT#Phase1#Popular#cell-gene-therapy+4
Trials 92Status Recruiting
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

Anti-CD19 CAR T-cells (Anti-CD19 CAR T-cells)

B Cell Malignancies · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 92Status Recruiting
CGTStandard DatabasestaleShanghai Ming Ju Biotechnology …Phase 2

CD19-targeted Chimeric Antigen Receptor (CAR, CD19-targeted Chimeric Antigen Receptor, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

Lymphoma, Non-Hodgkin; Diffuse Large B Cell Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 64Status Active
CGTStandard DatabasestaleAstraZenecaPhase 2

Epidermal growth factor receptor (EGFRv, Epidermal growth factor receptor, Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL)

Malignant Glioma; Glioblastoma · EGFR

#EGFR#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 61Status Active
CGTLimited DatastaleTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 60Status Recruiting
CGTLimited DatastaleTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 60Status Recruiting
CGTAAVLimited DatastaleBayerPhase 1

AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV, AAVrh.10hFXN, serotype rh.10 adeno-associated virus, AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN)

Friedreich Ataxia; Cardiomyopathies · Friedreich Ataxia

#FriedreichAtaxia#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 58Status Recruiting
CGTStandard DatabasestaleMinsk Scientific-Practical Cent…Phase 2

Anti-BCMA CAR-T cells (Anti-BCMA CAR-T cells)

Multiple Myeloma Refractory · BCMA

#BCMA#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 56Status Active
CGTStandard DatabasestaleJiangsu Topcel-KH Pharmaceutica…Phase 2

CD19 CAR T Arm (CD19 CAR T Arm)

Scleroderma, Systemic · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 56Status Recruiting
CGTLimited DatastaleNational Taiwan University Hosp…Phase 1

CD19 Chimeric Antigen Receptor (CAR, CD19 Chimeric Antigen Receptor, CD19 Chimeric Antigen Receptor (CAR) T Cells)

Relapsed/Refractory B-Cell Malignancies · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 56Status Active
CGTLimited DatastaleAllife Medical Science and Tech…Phase 2

Cytokine-induced killer cells (Cytokine-induced killer cells)

Ovarian Carcinoma · Cholangiocarcinoma

#Cholangiocarcinoma#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 56Status Recruiting
CGTLimited DatastaleCarbiogene Therapeutics Co. Ltd.Phase 2

anti-BCMA CAR-T (anti-BCMA CAR-T)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 56Status Recruiting
CGTStandard DatabasestaleNational Cancer Institute (NCI)Phase 2

Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-CAR PBL)

Primary Mediastinal B-cell Lymphoma; Diffuse, Large B-cell Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 55Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells)

Lymphoma, B-Cell; Lymphoma, Non-hodgkins · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 55Status Active

1 / 44 pages

← PreviousNext →